<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4904">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041453</url>
  </required_header>
  <id_info>
    <org_study_id>01-2019</org_study_id>
    <nct_id>NCT04041453</nct_id>
  </id_info>
  <brief_title>Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients</brief_title>
  <acronym>HI4T</acronym>
  <official_title>Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alejandro Krolewiecki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brock University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional del Centro de la Provincia de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Honduras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional de Salta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are four species of intestinal worms collectively known as soil-transmitted&#xD;
      helminthiasis (STH): Ancylostoma duodenale and Necator americanus (hookworms), Ascaris&#xD;
      lumbricoides (roundworms), and Trichuris trichiura (whipworms). These parasites affect over&#xD;
      two billion people and contribute to significant morbidity and disability, especially in high&#xD;
      risk groups, for example children, agricultural workers and pregnant women. In children, STH&#xD;
      are associated with impaired nutritional status evidenced by stunting, thinness and&#xD;
      underweight.&#xD;
&#xD;
      As is the case in most Latin America, STH are a public health problem in Honduras. The World&#xD;
      Health Organization (WHO) informs that more than 2.5 million children (under 15 years of age)&#xD;
      in the country are at risk of infection. To control these infections Honduras has established&#xD;
      a national deworming program that operates since 2001 but despite these efforts, the&#xD;
      prevalence of STH infections remains unacceptably high. This is especially true in rural&#xD;
      communities where prevalence can be as high as 70% of the children population.&#xD;
&#xD;
      Ivermectin (IVM) in combination with albendazole (ALB) has demonstrated the capacity to&#xD;
      improve efficacy compared to any of these drugs in monotherapy; the efficacy is however,&#xD;
      still inadequate in terms of cure rate, although egg reduction rates are significant.&#xD;
&#xD;
      The purpose of the current trial is to assess the safety and efficacy of 3 experimental&#xD;
      regimens for the treatment of infections by Trichuris trichiura in children in comparison&#xD;
      with the current standard of practice in Mass Drug Administration (MDA) campaigns. The&#xD;
      experimental regimens will explore the effect of multiple day regimens and high dose&#xD;
      ivermectin.&#xD;
&#xD;
      Treatment arms:&#xD;
&#xD;
        -  Group 1: single dose of ALB 400 mg. (active control arm). N:39&#xD;
&#xD;
        -  Group 2: single dose ALB 400mg + IVM 600µg/Kg. N: 57&#xD;
&#xD;
        -  Group 3: daily dose ALB 400mg for 3 consecutive days. N:24&#xD;
&#xD;
        -  Group 4: daily dose ALB 400mg + IVM 600µg for 3 consecutive days. N:57&#xD;
&#xD;
      Total Study Population: 177&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Actual">March 7, 2020</completion_date>
  <primary_completion_date type="Actual">March 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate</measure>
    <time_frame>21 days</time_frame>
    <description>Number of individuals cured from Trichuris trichiura infection using the duplicate Kato Katz laboratory method on a single sample of fresh stools as the measurement tool. Cure rate is defined as the absence of Trichuris trichiura eggs in post-treatment samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Egg Change Rate</measure>
    <time_frame>21 days</time_frame>
    <description>Calculation details: 100 x (1 - arithmetic mean fecal egg count post-intervention / arithmetic mean fecal egg count pre-intervention) Egg change rate was calculated across all participants, as described in reference: Levecke B et al., PLoS Negl Trop Dis. 2014;8(10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta Tubulin Resistance</measure>
    <time_frame>21days</time_frame>
    <description>Measurement of the incidence of mutations of tubulin in Trichuris trichiura eggs collected pre and post treatment using molecular biology techniques.&#xD;
This data is not available yet due to the COVID-19 pandemic, but the data will be available and reported in the future. Anticipated reporting date for this outcome measure is estimated by 2021 and will be confirmed once the pandemic is over.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Trichuris Infection</condition>
  <condition>Helminthiasis</condition>
  <arm_group>
    <arm_group_label>Albendazole 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 400mg in single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole/Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole 400mg x 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albendazole 400mg/day for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole/Ivermectin x 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.</description>
    <arm_group_label>Albendazole/Ivermectin</arm_group_label>
    <arm_group_label>Albendazole/Ivermectin x 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.</description>
    <arm_group_label>Albendazole 400mg</arm_group_label>
    <arm_group_label>Albendazole 400mg x 3</arm_group_label>
    <arm_group_label>Albendazole/Ivermectin</arm_group_label>
    <arm_group_label>Albendazole/Ivermectin x 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infection with T. trichiura by Kato Katz.&#xD;
&#xD;
          -  Body weight &gt;15kg.&#xD;
&#xD;
          -  Accepts participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Albendazole and/or mebendazol treatment in the previous 3 months.&#xD;
&#xD;
          -  Allergy to the study drugs&#xD;
&#xD;
          -  Acute medical conditions&#xD;
&#xD;
          -  Clinical trial participation in the previous 3 months.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro J Krolewiecki, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IIET - Universidad Nacional de Salta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IIET</name>
      <address>
        <city>Oran</city>
        <state>Salta</state>
        <zip>4530</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Autónoma de Honduras</name>
      <address>
        <city>Tegucigalpa</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Honduras</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <results_first_submitted>May 8, 2020</results_first_submitted>
  <results_first_submitted_qc>July 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2020</results_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Nacional de Salta</investigator_affiliation>
    <investigator_full_name>Alejandro Krolewiecki</investigator_full_name>
    <investigator_title>Investigador CIC CONICET</investigator_title>
  </responsible_party>
  <keyword>TRICHURIS</keyword>
  <keyword>STH</keyword>
  <keyword>IVERMECTIN</keyword>
  <keyword>ALBENDAZOLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helminthiasis</mesh_term>
    <mesh_term>Trichuriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication.</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After study data analysis completion, with submission for publication to a peer review journal..</ipd_time_frame>
    <ipd_access_criteria>Database will be made available through a publication.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT04041453/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albendazole 400mg</title>
          <description>Albendazole 400mg in single dose</description>
        </group>
        <group group_id="P2">
          <title>Albendazole/Ivermectin</title>
          <description>Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.</description>
        </group>
        <group group_id="P3">
          <title>Albendazole 400mg x 3</title>
          <description>Albendazole 400mg/day for 3 consecutive days.</description>
        </group>
        <group group_id="P4">
          <title>Albendazole/Ivermectin x 3</title>
          <description>Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albendazole 400mg</title>
          <description>Albendazole 400mg in single dose</description>
        </group>
        <group group_id="B2">
          <title>Albendazole/Ivermectin</title>
          <description>Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.</description>
        </group>
        <group group_id="B3">
          <title>Albendazole 400mg x 3</title>
          <description>Albendazole 400mg/day for 3 consecutive days</description>
        </group>
        <group group_id="B4">
          <title>Albendazole/Ivermectin x 3</title>
          <description>Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="58"/>
            <count group_id="B5" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="57"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="58"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="2.6"/>
                    <measurement group_id="B2" value="8.0" spread="2.2"/>
                    <measurement group_id="B3" value="8.5" spread="2.0"/>
                    <measurement group_id="B4" value="8.0" spread="2.2"/>
                    <measurement group_id="B5" value="8.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="57"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="58"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure Rate</title>
        <description>Number of individuals cured from Trichuris trichiura infection using the duplicate Kato Katz laboratory method on a single sample of fresh stools as the measurement tool. Cure rate is defined as the absence of Trichuris trichiura eggs in post-treatment samples.</description>
        <time_frame>21 days</time_frame>
        <population>The follow-up visit for efficacy assessment on Day 21 post-drug administration was not conducted in 52 subjects due to the outbreak of COVID-19 pandemic in Honduras which precluded completion of study visits in March 2020.&#xD;
Additional 7 subjects did not complete the study: 1 did not take the study medication, and 6 subjects were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Albendazole 400mg</title>
            <description>Albendazole 400mg in single dose</description>
          </group>
          <group group_id="O2">
            <title>Albendazole/Ivermectin</title>
            <description>Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.</description>
          </group>
          <group group_id="O3">
            <title>Albendazole 400mg x3</title>
            <description>Albendazole 400mg/day for 3 consecutive days.</description>
          </group>
          <group group_id="O4">
            <title>Albendazole/Ivermectin x 3</title>
            <description>Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate</title>
          <description>Number of individuals cured from Trichuris trichiura infection using the duplicate Kato Katz laboratory method on a single sample of fresh stools as the measurement tool. Cure rate is defined as the absence of Trichuris trichiura eggs in post-treatment samples.</description>
          <population>The follow-up visit for efficacy assessment on Day 21 post-drug administration was not conducted in 52 subjects due to the outbreak of COVID-19 pandemic in Honduras which precluded completion of study visits in March 2020.&#xD;
Additional 7 subjects did not complete the study: 1 did not take the study medication, and 6 subjects were lost to follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Egg Change Rate</title>
        <description>Calculation details: 100 x (1 - arithmetic mean fecal egg count post-intervention / arithmetic mean fecal egg count pre-intervention) Egg change rate was calculated across all participants, as described in reference: Levecke B et al., PLoS Negl Trop Dis. 2014;8(10).</description>
        <time_frame>21 days</time_frame>
        <population>The follow-up visit for efficacy assessment on Day 21 post-drug administration was not conducted in 52 subjects due to the outbreak of COVID-19 pandemic in Honduras which precluded completion of study visits in March 2020.&#xD;
Additional 7 subjects did not complete the study: 1 did not take the study medication, and 6 subjects were lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Albendazole 400mg</title>
            <description>Albendazole 400mg in single dose</description>
          </group>
          <group group_id="O2">
            <title>Albendazole/Ivermectin</title>
            <description>Albendazole 400mg + ivermectin 600mcg/kg in single dose.</description>
          </group>
          <group group_id="O3">
            <title>Albendazole x 3</title>
            <description>Albendazole 400mg/day for 3 consecutive days.</description>
          </group>
          <group group_id="O4">
            <title>Albendazole/Ivermectin x 3</title>
            <description>Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Egg Change Rate</title>
          <description>Calculation details: 100 x (1 - arithmetic mean fecal egg count post-intervention / arithmetic mean fecal egg count pre-intervention) Egg change rate was calculated across all participants, as described in reference: Levecke B et al., PLoS Negl Trop Dis. 2014;8(10).</description>
          <population>The follow-up visit for efficacy assessment on Day 21 post-drug administration was not conducted in 52 subjects due to the outbreak of COVID-19 pandemic in Honduras which precluded completion of study visits in March 2020.&#xD;
Additional 7 subjects did not complete the study: 1 did not take the study medication, and 6 subjects were lost to follow up.</population>
          <units>Percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta Tubulin Resistance</title>
        <description>Measurement of the incidence of mutations of tubulin in Trichuris trichiura eggs collected pre and post treatment using molecular biology techniques.&#xD;
This data is not available yet due to the COVID-19 pandemic, but the data will be available and reported in the future. Anticipated reporting date for this outcome measure is estimated by 2021 and will be confirmed once the pandemic is over.</description>
        <time_frame>21days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected since the subject's enrollment until end of study participation (Day 21).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Albendazole 400mg</title>
          <description>Albendazole 400mg in single dose</description>
        </group>
        <group group_id="E2">
          <title>Albendazole/Ivermectin</title>
          <description>Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose</description>
        </group>
        <group group_id="E3">
          <title>Albendazole 400mg x3</title>
          <description>Albendazole 400mg/day in 3 consecutive days</description>
        </group>
        <group group_id="E4">
          <title>Albendazole/Ivermectin x 3</title>
          <description>Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day in 3 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alejandro J Krolewiecki</name_or_title>
      <organization>Universidad Nacional de Salta</organization>
      <phone>+54 911 3183-8673</phone>
      <email>alekrol@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

